LONDON--(BUSINESS WIRE)-- DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today announced both the launch of Dexcom ONE+, a CGM ...
DexCom reported strong preliminary Q4 results, with topline figures above its earlier expectations. The company paired this ...
Time in range is a powerful metric for modern diabetes management - but a new survey finds less than half of people with insulin-treated diabetes are even using it.1 A recent UK survey found that ...
If you are wondering whether DexCom's current share price really reflects what you are getting for your money, you are not alone. The stock last closed at US$73.67, with returns of 4.2% over 7 days, 9 ...
DexCom treats about 2.5 million patients, with tons of room for more. The company's Q2 guidance bombshell tanked the stock. Competition from an unexpected source raises long-term concerns worth ...
DexCom (NASDAQ:DXCM) stock saw a notable increase of 16% on Friday following the announcement of its Q1 earnings and a share buyback program. The company’s first-quarter sales hit $1.04 billion, ...
The US Food and Drug Administration has cleared the Dexcom G7 15-Day Continuous Glucose Monitor (CGM) for people older than 18 with diabetes. It's the longest-lasting system on the market. The G7 ...
Sometimes the best way to fix a mistake is to double down on it—and that is just what DexCom is doing with its continuous glucose monitors for diabetes patients. It’s a decision that should pay off ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results